Clinical trials: Small Cell Carcinoma of Lung
Extensive-stage Small-cell Lung Cancer
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and tumor cell proliferation. The efficacy of Anlotinib as a third-line or beyond therapy for SCLC was confirmed in the ALTER1202 trial.
- Trial name
- NCT04675697
- Testing
- Platinum-etoposide+Anlotinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Xiangya Hospital of Central South University
NSCLC
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the…
- Trial name
- NCT04871997
- Where
- China
- Volunteers
- 373 people
- Sponsor
- Qian Chu
Small Cell Lung Cancer Limited Stage
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer.
- Trial name
- NCT06483282
- Testing
- Adebrelimab, Apatinib Mesylate, Etoposide
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jin Ying
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04919382
- Testing
- Atezolizumab, Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dwight Owen
Non-small Cell Lung Cancer Stage IIIB/IV
Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor
Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and…
- Trial name
- NCT06310915
- Testing
- Navelbine oral,Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Non-Small Cell Lung Cancer
Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will explore the effectiveness and safety of the combination therapy of anlotinib , penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05485350
- Testing
- Anlotinib Hydrochloride, penpulimab, SBRT
- Volunteers
- 32 people
- Sponsor
- Peking University Third Hospital
Non-small Cell Lung Cancer (NSCLC)
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as…
- Trial name
- STX-241 FIH (NCT06567015)
- Testing
- STX-241
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 171 people
- Sponsor
- Pierre Fabre Medicament
Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.
- Conditions
- Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- EMPIRE (NCT06084689)
- Testing
- Ezabenlimab + BI907828
- Where
- 6 sites in France
- Sponsor
- Institut Bergonié
Inoperable Early Stage Non-small Cell Lung Cancer
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC).
- Trial name
- PEARL-2 (NCT01138748)
- Testing
- hypofractionated radiation therapy
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Extensive-stage Small Cell Lung Cancer (SCLC)
YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
Globally, lung cancer stands as the foremost cause of cancer-related mortality. Among its subtypes, small cell lung cancer (SCLC) represents an exceptionally aggressive malignancy, accounting for approximately 15-20% of all lung…
- Trial name
- NCT07390565
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 308 people
- Sponsor
- LI FENG
Small Cell Lung Cancer
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
This study is a randomized, multi-center clinical trial. Patients are stratified according to performance status (ECOG 0, 1 vs 2) and institution. Patients are randomized to 1 of 2 treatment arms.
- Trial name
- NCT00349492
- Testing
- IP
- Where
- 14 sites in South Korea
- Volunteers
- 372 people
- Sponsor
- Clinical Research Center for Solid Tumor, Korea
Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer
LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer
The purpose of the study is to evaluate the usefulness and accuracy of the "LIFE-Lung Bronchoscopy" to identify early changes in lung tissues that show precancerous, cancer in situ (just beginning and not spread) and microscopic…
- Conditions
- Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00260598
- Testing
- LIFE Bronchoscopy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Pittsburgh
Solid Tumors, Pancreatic Cancer
CTS2190 Phase I /II Clinical Study in Patients
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types.
- Conditions
- Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
- Trial name
- NCT06224387
- Testing
- CTS2190 capsules
- Where
- 2 sites in China
- Volunteers
- 224 people
- Sponsor
- CytosinLab Therapeutics Co., Ltd.
NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Plasma-Adapted First-Line Pembro In NSCLC
This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and…
- Trial name
- NCT04166487
- Testing
- Pembrolizumab, PEMETREXED, CARBOPLATIN
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Julia K. Rotow, MD
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor…
- Trial name
- NCT01522833
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer, Nonsmall Cell, Stage I
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if Imbruvica (ibrutinib) alone and then in combination with Opdivo (nivolumab) can control NSCLC in patients who have received previous chemotherapy treatment.
- Trial name
- NCT02950038
- Testing
- Ibrutinib, Nivolumab
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Lymphoma
Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound
Aim: To investigate whether the novel 3rd generation FNB needle provides a better diagnostic accuracy than a standard FNA needle in EUS-B guided diagnosis of common deep seated thoracic malignancies (lung cancer and lymphoma).
- Conditions
- Lung Cancer, Lymphoma, Sarcoidosis
- Trial name
- IMPROVED (NCT06848738)
- Testing
- FNB, FNA
- Where
- 3 sites in Denmark
- Volunteers
- 362 people
- Sponsor
- Zealand University Hospital
Carcinoma, Non-Small-Cell Lung
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer.
- Trial name
- NCT02716038
- Testing
- MPDL3280A, Carboplatin, Nab-paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Columbia University
Carcinoma, Non-Small-Cell Lung
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant…
- Trial name
- Cybertaxcis II (NCT06627738)
- Testing
- Cyberknife irradiation
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Antoine Lacassagne
Lung Cancer
FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (^18FDG) positron emission tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- ACRIN6678 (NCT00424138)
- Testing
- FDG
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- American College of Radiology Imaging Network
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.